Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution
- 31 October 1999
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 26 (7), 781-790
- https://doi.org/10.1016/s0969-8051(99)00060-8
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- 186Re-Labeled Antibodies to p185HER2as HER2-Targeted Radioimmunopharmaceutical Agents: Comparison of Physical and Biological Characteristics with125I and131I-Labeled CounterpartsCancer Biotherapy & Radiopharmaceuticals, 1996
- The tyrosine kinase activity of the C‐erbB‐2 gene product (p185) is required for growth inhibition by anti‐p185 antibodies but not for the cytotoxicity of an anti‐p185‐ricin‐a chain immunotoxinInternational Journal of Cancer, 1994
- Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cellsInternational Journal of Cancer, 1994
- Characterization of cytotoxic activity of saporin anti‐gp185/HER‐2 immunotoxinsInternational Journal of Cancer, 1993
- Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs)Journal of Neuro-Oncology, 1993
- Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbb-2 (her-2/neu) gene product p185International Journal of Cancer, 1993
- Rat monoclonal antibodies to the external domain of the product of the C‐erbB‐2 proto‐oncogeneInternational Journal of Cancer, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature, 1984